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Protective immunity against human schistosome infection devel-
ops slowly, for reasons that are not yet fully understood. For many
decades, researchers have attempted to infer properties of the
immune response from epidemiological studies, withmathematical
models frequently being used to bridge the gap between immuno-
logical theory and population-level data on schistosome infection
and immune responses. Here, building upon earlier model findings,
stochastic individual-based models were used to identify model
structures consistent with observed field patterns of Schistosoma
haematobium infection and antibody responses, including their
distributions in cross-sectional surveys, and the observed treat-
ment-induced antibody switch. We found that the observed pat-
terns of infection and antibody were most consistent with models
in which a long-lived protective antibody response is stimulated by
the death of adult S. haematobium worms and reduces worm
fecundity. These findings are discussed with regard to current un-
derstanding of human immune responses to schistosome infection.
acquired immunity ∣ immunoepidemiology ∣ schistosomiasis
Schistosoma haematobium parasites infect more than 100 mil-lion people in sub-Saharan Africa and are responsible for a
heavy burden of disease (1, 2). Protective immunity against schis-
tosomes takes a long time to develop; the precise nature of the
protective immune response and the reasons for its slow develop-
ment are not fully understood, although several immune re-
sponses, antibodies in particular, have been associated with pro-
tection (3). Two hypotheses for the slow development of anti-S.
haematobium immunity have been put forward: firstly, that dying
worms are the main source of protective antigen, with exposure to
dying worms delayed by long parasite life spans (4); secondly, that
exposure to a certain threshold level of antigen is required before
a protective response is stimulated (5).
There is a long history of using epidemiological data to under-
stand the immune response to human schistosome infection
(6, 7), and mathematical models have played an important role
(8). A common approach has been testing the ability of models to
reproduce patterns seen in field data (9–11). Robust patterns
include the peaked age-intensity curve (7), the “peak shift” (in-
fection peaking at a higher level and younger age in populations
with higher exposure) (12), and an age-related switch in the
S. haematobium-specific antibody response (13, 14) (note that
this “switch” refers to a rapid change in the dominant antibody
isotype, not isotype switching of individual B cells). Pattern-
oriented modeling (POM), developed initially in ecology, uses
multiple different patterns to discriminate between possible mod-
els (15). Previous work using POM with deterministic models
could not distinguish between the two hypotheses for the slow
development of immunity against S. haematobium but greatly
narrowed down the range of model structures consistent with
these field patterns (16). The combination of the life cycle stage
that provided the main antigenic stimulus for each antibody
response, and the life cycle stage targeted by each antibody re-
sponse, was critical in determining whether all of these patterns
could be reproduced (16). These previous models did not take
into account heterogeneities in exposure to infection or look at
the distribution of infection or antibody responses across popula-
tions nor the impact of treatment on the immune response.
Schistosomes are highly aggregated among their human hosts,
such that many individuals harbor few or no schistosome worms,
while a few carry heavy parasite loads (17). Previous modeling
work suggests that this distribution arises from aggregation
between individuals in their rates of infection (related to water
exposure) (9), which observational studies confirm is highly
heterogeneous (18). Aggregated worm burdens may also result
from aggregation in the number of worms acquired per contact
(10, 19). Levels of S. haematobium-specific antibody are also
highly aggregated. Isotypes that demonstrate an age-related
switch have a dichotomous relationship, with individuals rarely
producing high levels of both isotypes (13, 20). As well as occur-
ring naturally with age, this antibody switch is observed in young-
er children following praziquantel treatment (20, 21).
Here, we extend our earlier POM analysis (16), incorporating
heterogeneous exposure into the successful model structures
using stochastic individual-based models, and testing whether
these models can also reproduce the distributions of S. haemato-
bium infection and antibody seen in the field and the post-treat-
ment antibody switch. We find that only a very limited set of
models are capable of reproducing the field data, providing novel
insights into the immunological processes that lead to these
observed patterns.
Results
Baseline Analysis: Cross-Sectional Criteria. The initial analysis used
the baseline parameter values to assess whether each model could
meet all of the “cross-sectional” criteria listed in Table 1. Only
three of the different model structures tested were ever able
to meet all of these criteria over a twofold change in population
contact rate (Table 2). These models all included an antigen
threshold and all had the nonprotective response stimulated by
egg antigens, with the protective antibody response stimulated by
antigen from cercariae, live worms or dying worms. In all three
models the protective response reduced worm fecundity.
One of the cross-regulation models was able to meet all of the
cross-sectional criteria for 12 individual parameter sets, although
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not over a twofold change in population contact rate (Table 2). In
this model the protective antibody response was stimulated by
antigen from dying worms and reduced worm fecundity, and
the nonprotective antibody response was stimulated by egg stage
antigens.
Importance of Different Criteria.The relative importance of the dif-
ferent criteria in excluding parameter combinations was assessed
for the baseline analysis. The number of individual simulations
passing each criterion, and passing each pair of criteria, was
counted. For both cross-regulation and threshold models, the cri-
teria least likely to be passed were the antibody switch (failed by
85% and 70% of simulations, respectively) and S. haematobium
infection prevalence in both 6–14- and 15–34-year-olds (at least
one of these prevalence criteria was failed by 86% and 90% of
simulations for the cross-regulation and threshold models, re-
spectively). Simulations that gave reduced infection levels in
adults were more likely to pass the prevalence criteria, and those
passing the prevalence criteria were in general more likely to pass
the aggregation and antibody switch criteria. A number of trade
offs were seen between different criteria; most notably, simula-
tions passing the peak age criterion were less likely to pass the
criterion for prevalence in 6–14-year-olds (this pair of criteria
was failed by 97% of all simulations). The majority of simulations
failed on multiple criteria, with only 5% failing on a single criter-
ion alone. All of the criteria were found to be discriminatory.
Inclusion of Treatment.The models that were able to meet all of the
criteria over a twofold change in population contact rate were
further analyzed for their ability to reproduce the observed anti-
body switch after treatment of children aged 6–15 years old. A
range of different treatment efficacies and post-treatment levels
of transmission reduction were investigated (see SI Text for
details). Only the model with dying worm antigens stimulating
the protective antibody response was able to reproduce the
post-treatment antibody switch (Table 2) for a subset of the para-
meters that reproduced all of the cross-sectional data patterns.
The number of parameter sets reproducing the post-treatment
antibody switch was robust to the level of treatment efficacy and
transmission reduction over the ranges explored. The cross-
regulation model that was able to meet all of the cross-sectional
criteria for individual parameter sets was also able to reproduce
the antibody switch after treatment.
Sensitivity Analysis. Sensitivity analysis was carried out on the two
model structures which were able to reproduce the antibody
Table 1. Criteria used to determine whether models replicated age-related and distributional patterns of infection and antibody seen in
cross-sectional and post-treatment field data
Pattern identified in field data Criterion applied to model output Source
Cross-sectional
Prevalence of infection by urine test Prevalence of egg positives 5–80% for 6–14 year olds and for 15–34 year olds Refs. 14, 44
Peaked age intensity curve Maximum level of infection occurs between age of 6–23 years old Refs. 7, 14, 16, 44
Reduced infection level in adults Infection level in 24–34 year old age group <40% of peak age group Refs. 7, 14, 16, 44
Peak shift Peak infection intensity is lower and occurs in the same or older age group
when infection rate is halved
Ref. 12
Aggregated egg output Standardized variance (SV) of mean egg output 2–60 for whole population,
for 6–14 year olds and for 15–34 year olds
Refs. 14, 44
Antibody switch Spearman’s ρ for association between two antibody responses < − 0.2 Refs. 13, 14, 20
Antibody switch after age of
infection peak
Initial (nonprotective) antibody response first falls below its midpoint value in
the same or a later age group than peak infection
Refs. 13, 14
Post-treatment
Antibody switch after treatment A2 is ≥200% and A1 is ≤50% of respective pre-treatment levels at both 18
and 36 wk post-treatment
Ref. 20
Table 2. Relative success of different model structures in meeting criteria
Immune mechanism Life cycle stage
No. of parameter sets passing
following criteria:
Antigen for A2 Targeted by A2 Antigen for A1 Cross-sectional
Cross-sectional
and post-treatment
Cross-regulation Cercariae Cercariae Live worms 0 0
Cercariae Cercariae Dying worms 0 0
Cercariae Cercariae Eggs 0 0
Live worms Eggs Cercariae 0 0
Live worms Eggs Live worms 0 0
Live worms Eggs Dying worms 0 0
Live worms Eggs Eggs 0 0
Dying worms Cercariae Live worms 0 0
Dying worms Cercariae Eggs 0 0
Dying worms Eggs Cercariae 0 0
Dying worms Eggs Live worms 0 0
Dying worms Eggs Dying worms 0 0
Dying worms Eggs Eggs 0* 0
Antigen threshold Cercariae Cercariae Live worms 0 0
Cercariae Cercariae Dying worms 0 0
Cercariae Cercariae Eggs 0 0
Cercariae Eggs Eggs 22 0
Live worms Eggs Eggs 254 0
Dying worms Eggs Eggs 48 32
Eggs Eggs Eggs 0 0
*For this model, 12 individual parameter sets were able to meet all of the criteria, but none of these could meet the criteria over a twofold change in
population infection rate.
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switch after treatment: one with cross-regulation and one with
an antigen threshold, which both had an anti-fecundity, dying
worm-stimulated, protective antibody response and egg-stimu-
lated, nonprotective antibody. Each of the parameters governing
the stochastic model processes was varied separately in turn,
while varying all other parameters over their full baseline ranges.
Fig. 1 shows the number of parameter sets that were able to pass
all of the cross-sectional and the post-treatment criteria over a
twofold change in maximum contact rate when each of the sto-
chastic process parameters was varied in turn. For the cross-reg-
ulation model (Fig. 1A), the criteria were only all passed with
moderate cercarial aggregation (d ¼ 10) or with low egg output
per worm (ε ¼ 0.1). For the antigen threshold model, it was
found that both the aggregation of the underlying contact rates
between individuals and the rate at which this contact level was
resampled affected whether the models could meet all of the cri-
teria. Poisson distributed contacts (k1 ¼∞) and frequent resam-
pling of contact rates (ϕ ¼ 0.5 y−1) both prevented the models
from reproducing field patterns (Fig. 1B). These results are
not independent, because more frequent resampling of contact
rates reduces the overall aggregation of contact between indivi-
duals. A moderate increase in aggregation of the underlying con-
tact rate to the maximum level reported in ref. 22 (k1 ¼ 0.4), or
perfect predisposition (ϕ ¼ 0), both increased the number of
parameter sets that were able to meet all of the criteria. Increased
cercarial aggregation (d ¼ 10, d ¼ 100) and reduced egg output
per worm (ε ¼ 0.1) all increased the number of parameter sets
meeting all criteria, while increased egg output (ε ¼ 10) made
little difference, and reducing the aggregation of eggs per worm
found in urine (using a Poisson distribution, kE ¼ ∞) reduced the
number of parameter sets able to meet all of the criteria.
Parameter Distributions. The decay rates for the two plasma cell
populations in successful parameter sets (summed across the
baseline and sensitivity analysis results) are shown in Fig. 2.
Similar patterns were seen for both the cross-regulation model
(Fig. 2A) and the antigen threshold model (Fig. 2B). For all of
the successful parameter sets, there was relatively rapid decay of
the initial antibody response (A1) of 8–80 y−1 (half-life 3.2–32 d),
with slower decay of the protective antibody response (A2) for
almost all parameter combinations of 0.008–0.8 y−1 (half-life
of 10 mon–87 y). Within these ranges there was little apparent
preference for particular values or combinations of the two decay
rates. Four parameter combinations in the antigen threshold
models had more rapid A2 decay of 8 y−1 (half-life 32 d).
Antibody Aggregation and Co-distributions. All of the models that
passed all of the criteria gave aggregated distributions for both
antibody responses. Visual inspection of antibody co-distribu-
tions for randomly selected parameter sets (Fig. 3) confirmed
that the models had reproduced the dichotomous relationship
which was seen in field data (20).
Discussion
As hypothesized, it was found that dying worms had to provide
the main antigenic stimulus for a protective antibody response in
order to reproduce field patterns of S. haematobium infection and
antibody. Additionally, it was found that the protective antibody
response had to reduce worm fecundity, and the nonprotective
antibody response had to be stimulated by eggs. Other models
most commonly failed because they could not reproduce the
A
B
Fig. 1. Results of univariate sensitivity analysis. Panels show the number of
parameter combinations tested that meet all criteria (cross-sectional and
post-treatment) over a twofold change in maximal contact rate when the
following parameters are changed individually as shown: the scale parameter
for the gamma distribution from which individual contact rates are drawn
(k1), the probability with which contact rates are resampled (ϕ), the aggre-
gation of cercariae acquired per contact (d), the mean number of eggs per
worm per 10 mL urine (ε), and the scale parameter for the gamma distribu-
tion from which the number of eggs per worm is drawn (kE). Baseline values
are: k1 ¼ 0.5, ϕ ¼ 0.05 y−1, d ¼ 1, ε ¼ 1, kE ¼ 1. (A) Cross-regulation model,
(B) antigen threshold model.
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Fig. 2. Distribution of plasma cell decay rates in successful parameter
combinations. The frequency of different combinations of decay rates for
the two plasma cell populations are shown for models that were able to meet
all of the cross-sectional and post-treatment criteria, in either the baseline or
the univariate sensitivity analysis. (A) Cross-regulation models. (B) Antigen
threshold models. Bars are drawn for all combinations of plasma cell decay
rates that were used. Black bars indicate a frequency of 0, gray bars a
frequency > 0.
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antibody switch or give plausible infection prevalence. Models in-
cluding either cross-regulation or an antigen threshold were able
to reproduce all of the pre- and post-treatment infection and anti-
body patterns. The analysis suggested that the B cell populations
that produce the different antibody responses have different in-
trinsic decay rates, with the cells producing the initial antibody
response decaying more rapidly than those producing protective
antibody. It also showed that high aggregation in contact rates
and low rates of change of contact rates (in line with levels mea-
sured in the field) are necessary for models to reproduce the
observed data patterns.
The finding that dying worms provide the main source of pro-
tective antigen fits with several studies showing that praziquantel
treatment, which kills adult schistosomes but has little effect on
immature worms (23), can boost antibody responses associated
with protection against reinfection (20, 24). The finding that pro-
tective immunity is likely to principally target fecundity is sup-
ported by the findings that lower levels of S. haematobium egg
output were found relative to levels of circulating anodic antigen
(a marker for worm burden) in adults than in children (25), and
that S. haematobium fecundity is reduced by the immune re-
sponse in mice (26). This analysis suggests that the most likely
antigens to stimulate a protective response are ones that have
their immune recognition boosted by treatment and that stimu-
late a primarily anti-fecundity response. Previously identified
S. haematobium antigens that were only serologically recognized
post-treatment include tropomyosin, paramyosin, triose phos-
phate isomerase, and glutathione S-transferase (GST) (27). Vac-
cinations of mice and natural mammalian hosts with S. japonicum
tropomyosin and paramyosin lead to modest reductions in worm
burden upon challenge, and often to an even greater reduction in
egg output (28, 29), although this is not always seen (30, 31). One
study has suggested that S. japonicum triose phosphate isomerase
induces anti-fecundity effects (32), but other studies show a simi-
lar reduction in worm burden as in egg output (33), suggesting
other immune targets. The antigen that has been most frequently
associated with an anti-fecundity response is GST, which has been
shown to reduce S. haematobium worm fecundity in baboons (34)
as well as S. mansoni fecundity in mice (35) and S. japonicum
fecundity in natural hosts (30).
For virtually all of the successful models, the B cell population
producing protective antibody had a slower natural decay rate
than the B cell population producing the initial (nonprotective)
response. Short- and long-lived subsets of plasma B cells specific
for a range of viral and bacterial antigens have been described,
which have differing reported decay rates (36, 37). Different
schistosome antigens may stimulate populations of plasma cells
with differing decay rates.
The balance between different isotypes may also influence the
expression of protection. Recent proteomics studies indicate that
the isotypes IgA, IgE, IgG1, and IgG4 commonly recognise some
schistosome antigens but also differentially recognise others and
that heavily infected people do not have high ratios of IgG1/IgA
or IgE/IgG4 (38).
It was found that relatively high levels of aggregation of indi-
vidual contact rates had to be maintained, with low rates of
change of individual contact rates, in order to reproduce field pat-
terns. The values used in the baseline analysis, of k1 ¼ 0.5 and
ϕ ¼ 0.05 y−1, which were both estimated from field data, were
sufficient to reproduce all of the required patterns. Aggregation
of cercarial acquisition increased the number of parameter sets
for which models met all of the criteria but was not essential, and
both reduced mean egg output per worm and increased aggrega-
tion of egg output also enhanced the ability of the models to meet
the criteria, because both decrease the measured prevalence of
infection. The level of aggregation of egg output used in most
of the models was estimated from S. mansoni data (39), in the
absence of similar estimates for S. haematobium. The reduced
level of mean egg output per worm (0.1 per worm per 10 mL
urine) that improved model performance is slightly lower than
previous estimates (40, 41) but plausible given the considerable
uncertainty in egg production rates for S. haematobium and var-
iation in urine output. Exposure to cercariae is difficult to quan-
tify directly, but there is no good evidence that exposure is highly
aggregated (19) or, equivalently, that occasional large exposures
are more likely than frequent small exposures (42). Aggregation
in individual exposure levels was sufficient to explain antibody
aggregation as well as aggregation in infection intensities, without
needing to additionally consider other potential sources of anti-
body aggregation such as variability in individual immune com-
petence, although such variability is not excluded.
In conclusion, this work has shown that observed pre-treat-
ment, age-related patterns of S. haematobium infection and anti-
body and short-term, post-treatment changes in antibody levels,
are consistent with the following immunological model. In young-
er, untreated individuals resident in endemic areas, secreted egg
antigens stimulate an antibody response that is produced by
short-lived plasma cells (with any associated memory B cell re-
sponse also being short-lived) and is essentially nonprotective.
Cumulative deaths of adult S. haematobium worms eventually re-
lease a sufficient quantity of antigens (such as GST) to stimulate a
different antibody response that is produced by long-lived plasma
cells (or is driven by antigen-independent stimulation of a long-
lived memory B cell population) that reduces S. haematobium
fecundity. The integration of immunological and epidemiological
processes developed here provides powerful insights into the
essential elements of a highly complex host-pathogen interaction,
and we hope that this kind of analysis will also prove helpful for
understanding other infectious diseases of humans.
Materials and Methods
Model. An individual-based, stochastic, discrete-time model was used to
describe changes in worm burden and the level of two separate antibody
responses with age for people living in an area with stably transmitted en-
demic schistosome infection. The model structure, assumptions, and para-
meter values are all informed by current understanding of immune responses
to human S. haematobium infection. Antibody responses are explicitly mod-
eled because they have been well characterized, are frequently associated
with protection, and have a clearly defined cellular source, B cells, for which
the maturation pathways are well known. The immune response is modeled
as populations of antibody-producing plasma B cells, but this may equiva-
lently represent the dynamics of memory B cells with continual antigen-
independent activation to short-lived plasma cells. T cells are assumed to con-
tribute to the generation and maintenance of the antibody response but are
not explicitly included. The model was based upon a framework used in ear-
lier deterministic population-level models (16), with worm survival assumed
to be approximately Gaussian distributed. The model structures used were
those that met a panel of criteria over the greatest region of parameter space
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Fig. 3. Antibody co-distributions in the model outputs, shown for two
example parameter sets. (A) Cross-regulation model, parameters used:
Λpmax ¼ 25, 1∕μ ¼ 10, γ1 ¼ 80, γ2 ¼ 0.008, η ¼ 0.256, ρ ¼ 0.1, k1 ¼ 0.5,
ϕ ¼ 0.05, kE ¼ 1, d ¼ 10. (B) Antigen threshold model, parameters used:
Λpmax ¼ 100, 1∕μ ¼ 6.5, γ1 ¼ 80, γ2 ¼ 0.08, η ¼ 1.024, T ¼ 250, k1 ¼ 0.5,
ϕ ¼ 0.05, kE ¼ 1, d ¼ 100. White squares 0–14-year-olds, black circles
15–34-year-olds.
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tested in the deterministic analysis (16) and had either cross-regulation of the
short-lived antibody response or an antigen threshold for the longer-lived
antibody response. Cross-regulation was included in this and our earlier mod-
els to test whether this was necessary to generate the switch in the antibody
response. In the deterministic analysis, every possible combination of schisto-
some life-cycle stage stimulating and being targeted by the antibody
response was considered (16); here we only look at those combinations that
gave outputs in the deterministic analysis consistent with field data. In the
deterministic framework, it was found that in general the shorter-lived anti-
body response (A1) must have little or no protective effect, so it was assumed
here that only the longer-lived antibody response (A2) was protective.
A schematic diagram of the model is shown in Fig. 4. Water contact, worm
acquisition and death, and measured egg output are all modeled as stochas-
tic processes, while antibody development and immune stimulation by egg
antigens are modeled deterministically. In line with field observations (43), an
individual’s contact rate (ΛðaÞ) is assumed to increase linearly with age up to
age ac and then remains constant at Λm. Λm varies between individuals and is
drawn from a gamma distribution with a mean equal to the population aver-
age and shape parameter k1. To allow for changes in contact rate due to mov-
ing house or school, this individual contact rate is reselected with a yearly
probability ϕ. Daily contacts are Poisson distributed around ΛðaÞ. It is as-
sumed that d cercariae are acquired with a probability 1∕d per contact.
New cercariae may be killed upon entry into the host by an anti-reinfection
antibody response; otherwise they become worms and pass through nine
worm compartments to give approximately Gaussian distributed survival.
The number of eggs within the host (E) is assumed to be proportional to cur-
rent worm burden but reduced by anti-fecundity antibody. Measured egg
output is calculated as the arithmetic mean of three separate “samples”
(as is collected in the field), each drawn from a negative binomial distribution
with mean εEðaÞ (where ε is the mean number of eggs output in 10 mL urine
per worm per day) and aggregation parameter kE. Two antibody responses
(A1 and A2) are modeled as separate populations of plasma cells, each having
a single life stage as its principal source of antigen: cercariae, live worms,
dying worms, or (within-host) eggs. Each plasma cell population expands
at a rate proportional to the level of antigen stimulating that response
and decays exponentially. In models with cross-regulation, the growth rate
of the nonprotective antibody response, A1, is reduced as a function of the
level of antigen stimulating the protective antibody response. For models
with an antigen threshold, a cumulative tally of exposure to antigen is kept,
and protective antibody (A2) is only made if cumulative antigen exposure
exceeds a threshold level. The model equations and a detailed description
of the model are given in SI Text.
For each population, separate simulations were run for 161 individuals,
updated at daily steps, with infection and antibody levels recorded at a single
age for each individual to give simulated cross-sectional data sets for com-
parison with field data (14).
The impact of treatment is assessed in the model by introducing a single
round of praziquantel treatment (assumed to be at the WHO-recommended
dose of 40 mg∕kg body weight) for all individuals aged 6–15 years old. The
effects of treatment are assumed to be (i) a decline in worm burden, (ii) a
boost to the level of dying worm antigen (proportional to the number of
worms killed by treatment), and (iii) a reduction in transmission after treat-
ment, modeled as a reduction in the probability of infection per contact on
all subsequent days.
Model Criteria. Criteria were drawn up to test whether models could repro-
duce robust patterns of S. haematobium infection and antibody seen in field
data. The following cross-sectional patterns were characterized: infection
prevalence (by age), the peaked age intensity curve, reduced infection level
in adults, the peak shift, aggregation of infection (by age), the antibody
switch, and the age at which the antibody switch occurs. Changes in antibody
levels after treatment were included in an additional criterion. Antibody ag-
gregation was also assessed but was not included as a formal criterion, be-
cause the range of levels obtained from field data was too broad to be
informative. The data and methods used to draw up the criteria for the
peaked age intensity curve, reduced infection level in adults, the peak shift,
the antibody switch, and the age of the antibody switch have been previously
described (16). Prevalence and aggregation of S. haematobium infection
were calculated from data from six Zimbabwean communities (14, 44, 45)
for the whole population and for two age groups (6–14- and 15–34-year-olds)
and used to determine ranges for the relevant criteria. Infection aggregation
was characterized by the standardized variance, calculated as σ 2∕x¯ 2. For the
post-treatment antibody switch, the extent of the switch and the length of
time over which the antibody responses remained switched were analyzed
using antibody data from treated children (20). The criteria are all listed
and defined in Table 1, and the data and methods are described in more de-
tail in SI Text.
Model Analysis. Simulations were run for each of the successful combinations
of antigen and antibody target identified from deterministic analysis (16). In
the initial baseline analysis, the parameters governing the stochastic pro-
cesses were kept constant and the parameters determining mean population
infection rate, worm life span, antibody strength, strength of cross-regula-
tion/antigen threshold level, and plasma cell decay rates were each varied
across plausible ranges (see SI Text for details). All possible combinations
of these parameters were used in turn, giving 4,725 parameter sets for each
antigen-target combination. Each simulated cross-sectional dataset was ana-
lyzed in the same way as the field data used to draw up the criteria, and the
POM approach was used to identify models that could simultaneously meet
all of the cross-sectional criteria (more details about POM are given in SI Text).
Successful parameter combinations had to meet these criteria over a twofold
change in contact rate, because all of these patterns were identified in multi-
ple populations with different levels of infection. Performance curves were
drawn for a selection of parameter sets to determine how many replicate
simulations were needed to obtain a stable estimate of the proportion of
repeat simulations passing all of the criteria. Four-hundred repeat simula-
tions were found to be sufficient. A threshold percentage of simulations
passing all criteria was used to define “successful” parameter combinations;
this threshold was set at 50%, which was found to provide a good level of
discrimination while allowing that the criteria represent typical patterns,
not hard-and-fast rules. No parameter combinations were accepted using
a higher threshold of 95%.
Parameter sets meeting the cross-sectional criteria were tested for their
ability to reproduce the treatment-induced antibody switch in 6–15-year-
olds. Univariate sensitivity analysis was carried out on models that were able
to reproduce both the cross-sectional and post-treatment patterns, varying
each of the parameters governing the stochastic processes in the model in
turn. These models were tested for their ability to reproduce both the cross-
sectional and post-treatment patterns. Antibody distributions were assessed
visually for a subset of themodels that passed all of the criteria for qualitative
comparison with the field data.
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Fig. 4. Schematic diagram of the model. This shows the main state variables,
worm burden (P), and two populations of plasma cells (A1 and A2), with
production of eggs (E). A single worm compartment is shown for clarity.
Cross-regulation of the nonprotective response (of strength ρ) is shown by
the dashed line.
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